Divi's Laboratories Limited (DIVISLAB) — Board Meeting | 11 February 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Divi's Laboratories reported consolidated total income of ₹2,692 crores for Q3 FY26, up 12.1% YoY from ₹2,401 crores. Profit before tax (after ₹74 crores labour code impact) reached ₹780 crores versus ₹726 crores YoY. Profit after tax declined to ₹583 crores from ₹589 crores YoY. For nine months ended December 31, 2025, consolidated total income stood at ₹8,081 crores, up 14.8% YoY from ₹7,041 crores, with PAT of ₹1,817 crores versus ₹1,529 crores YoY.

📄 View Original Announcement (PDF)

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

📊 More DIVISLAB filings

See all DIVISLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day